U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO4.H2O
Molecular Weight 394.4769
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUOCORTOLONE MONOHYDRATE

SMILES

O.C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO

InChI

InChIKey=XMXIGEQXHQRVHJ-ABJXWZFZSA-N
InChI=1S/C22H29FO4.H2O/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24;/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3;1H2/t11-,13+,14+,16+,17+,19-,20-,21+,22+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C22H29FO4
Molecular Weight 376.4617
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.druginfosys.com/Drug.aspx?DrugCode=1121&DrugName=Fluocortolone&type=1

Fluocortolone is a topical corticosteroid (class of steroid hormones formed in the adrenal gland). Is primary indicated in condition like, Ana fissure, Dermatosis haemorrhoids, proctitis. The signs and symptoms that are produced after the acute overdosage include convulsions, respiratory arrest, allergic skin reactions. Glucocorticoids, such as fluocortolone, act through nuclear hormone receptors Schaaf and Cidlowski (2002). The two members of this family are glucocorticoid receptor (GR) type I and GR type I I. Activation of these sites alters gene expression of endogenous agents that influence immune and inflammatory responses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions
PubMed

PubMed

TitleDatePubMed
Operational post-keratopasty graft tolerance due to differential HLAMatchmaker matching.
2010-11-11
Update on the management of chronic eczema: new approaches and emerging treatment options.
2010-07-28
Prevention and treatment of intertrigo in large skin folds of adults: a systematic review.
2010-07-13
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.
2010-04
A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.
2010-01
Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study.
2009-11
[Retinochoroidopathy after intravitreal anti-VEGF treatment].
2009-08
Adalimumab for the treatment of fistulas in patients with Crohn's disease.
2009-07
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples.
2009-04
Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients.
2009-04
Transrepression and transactivation potencies of inhaled glucocorticoids.
2008-12
Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis.
2008-05
Varicella chorioretinitis.
2007-12
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).
2007-06
[Sudden hearing loss in a patient with a 3-mm acoustic tumor].
2007
Oral and intralesional steroid therapy in giant cell granuloma.
2006-06
An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty.
2006-03-15
Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis.
2006
[Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study].
2005-05
Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.
2005-04-27
Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study.
2005-02
Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
2004-11
Syphilitic interstitial keratitis: treatment with immunosuppressive drug combination therapy.
2004-07
Childhood lichen planus with nail involvement: a case.
2003-12-31
[Bilateral uveitis intermedia. A 15-year clinical course].
2003-12
Orbital myositis in a patient with primary biliary cirrhosis: successful treatment with methotrexate and corticosteroids.
2003-11
Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis.
2003-08
An integrative approach to eczema (atopic dermatitis).
2003-02-25
A case of cutaneous delayed-type allergy to oral dexamethasone and to betamethasone.
2002
Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
2001-06
Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial.
2001-04
Contact allergies to topical corticosteroids: 10 cases of contact dermatitis.
1991-08
Patents

Sample Use Guides

adult: 0.025 %; Frequency: 8 hours
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 10:33:57 GMT 2025
Edited
by admin
on Wed Apr 02 10:33:57 GMT 2025
Record UNII
Z9Y6DNY6M2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUOCORTOLONE MONOHYDRATE
Preferred Name English
Code System Code Type Description
FDA UNII
Z9Y6DNY6M2
Created by admin on Wed Apr 02 10:33:57 GMT 2025 , Edited by admin on Wed Apr 02 10:33:57 GMT 2025
PRIMARY
PUBCHEM
66605376
Created by admin on Wed Apr 02 10:33:57 GMT 2025 , Edited by admin on Wed Apr 02 10:33:57 GMT 2025
PRIMARY
SMS_ID
100000162566
Created by admin on Wed Apr 02 10:33:57 GMT 2025 , Edited by admin on Wed Apr 02 10:33:57 GMT 2025
PRIMARY
CAS
910908-82-6
Created by admin on Wed Apr 02 10:33:57 GMT 2025 , Edited by admin on Wed Apr 02 10:33:57 GMT 2025
NON-SPECIFIC STOICHIOMETRY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY